Zenagamtide was first known as amycretin. It brings complementary hormone signals into one engineered peptide, rather than combining two separate medicines.

Novo Nordisk developed it in Denmark. Agnes Gasiorek and colleagues reported an early oral study in twenty twenty-five, conducted at a research unit in San Antonio, Texas.

The peptide activates GLP-one, amylin, and calcitonin receptors, connecting glucose regulation with appetite and fullness. These structural views show receptor architecture, not a zenagamtide binding experiment.

Scientists are studying oral and injectable formulations. Separate phase two analyses included one hundred eighty-six oral participants and two hundred sixty-two injectable participants, with type two diabetes.

At thirty-six weeks, estimated haemoglobin A-one-C reductions ranged from zero point nine to one point seven percentage points in injectable groups, and zero point nine to one point four in oral groups.

These are separate route analyses, not a head-to-head comparison. Gastrointestinal and serious adverse events were reported. Long-term safety still requires more evidence.

At the October thirteen, twenty twenty-six cutoff, zenagamtide remains investigational. AMAZE studies obesity; AMBITION studies type two diabetes. Next: eloralintide.

Peptides in 2. World Peptide Foundation. Every experience matters.